Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus.
- Author:
Jung Hwa JUNG
1
;
Udaya S TANTRY
;
Paul A GURBEL
;
Young Hoon JEONG
Author Information
- Publication Type:Review
- Keywords: Aspirin; Atherothrombosis; Diabetes; Platelet; P2Y12 inhibitor
- MeSH: Aspirin; Atherosclerosis; Blood Platelets; Diabetes Mellitus*; Humans; Platelet Aggregation Inhibitors; Thrombophilia
- From:Diabetes & Metabolism Journal 2015;39(2):95-113
- CountryRepublic of Korea
- Language:English
- Abstract: Patients with diabetes mellitus (DM) have accelerated atherosclerosis with an increased risk for atherothrombotic cardiovascular complications. A state of high platelet reactivity and activation, hypercoagulability (prothrombotic state) and a subdued response to standard antiplatelet agents may explain high rate of adverse cardiovascular events in patients with DM. Several antithrombotic treatment strategies have been developed to control the prothrombotic state in patients with DM: dose modification of commonly used agents; use of potent agents; and addition of a third antithrombotic drug (triple therapy) to commonly prescribed dual antiplatelet therapy of aspirin and a P2Y12 inhibitor. The present review aims to provide an overview of the current knowledge on platelet abnormalities in patients with DM, focusing on the challenges and perspectives of antiplatelet treatment strategies in this population.
